Related Experiment Videos

Monocyte procoagulant activity and plasminogen activator. Role in human renal allograft rejection

Transplantation
|October 1, 1985
PubMed

Insights

Monocyte procoagulant activity (MCPA) may play a role in renal allograft rejection. Elevated MCPA levels can predict rejection episodes, potentially aiding clinical management.

Area of Science:

  • Nephrology
  • Immunology
  • Hematology

Background:

  • The precise mechanisms underlying renal allograft rejection remain incompletely elucidated.
  • Monocyte procoagulant activity (MCPA) is a potential factor in transplant rejection pathogenesis.

Purpose of the Study:

  • To investigate the role of MCPA induction in the pathogenesis of renal allograft rejection.
  • To assess the utility of MCPA as an early predictor of rejection episodes.

Main Methods:

  • MCPA assay performed using a one-stage clotting assay in normal and factor-VII-deficient plasma.
  • Daily assessment of MCPA in 18 renal allograft recipients.
  • Comparison of MCPA levels with clinical diagnosis of rejection episodes (RE).

Main Results:

  • No significant increase in spontaneous MCPA was observed in end-stage renal failure patients or post-operation patients compared to controls.
  • Elevated MCPA levels predicted rejection episodes in 12 out of 18 patients, preceding clinical diagnosis by at least 24 hours.
  • MCPA demonstrated a low false-positive rate (7) and a very low false-negative rate (1), showing temporal correlation with RE in 8 cases.

Conclusions:

  • MCPA is likely a prothrombinase, requiring only prothrombin and fibrinogen for activity.
  • MCPA may be implicated in the pathogenesis of allograft rejection.
  • MCPA shows promise as a valuable adjunct for the clinical management of renal allograft rejection.

Related Concept Videos